Daiichi Sankyo, Inc. (United States)

Daiichi Sankyo is a global pharmaceutical company with expertise in oncology and cardiovascular medicine. The company developed ENHERTU (trastuzumab deruxtecan), a groundbreaking antibody-drug conjugate for HER2-positive breast cancer and other solid tumors, in collaboration with AstraZeneca. Additional products include Lixiana/Savaysa (edoxaban) for blood clots and Injectafer for iron deficiency anemia. Daiichi Sankyo’s innovative oncology pipeline transforms cancer treatment.